Amgen ends rilotumumab in gastric cancer; cautions outside investigators
This article was originally published in Scrip
Executive Summary
Amgen terminated all of its clinical trials for rilotumumab in the treatment of gastric cancer following a planned Phase III safety review and a spokesman told Scrip that the company has encouraged outside investigators to assess the benefits of continuing their studies.